Remove 2001 Remove Cannabinoids Remove Chronic Pain Remove Clinical Trials
article thumbnail

Pushing Cannabis into Modern Healthcare

CannaTech

Canada has been at the forefront of shaping much of the rhetoric surrounding cannabis since 2001. But this gap restricts patient access to a medicine that can offer relief to a long list of conditions including chronic pain, seizures attributed to epilepsy, as well as mood disorders such as anxiety and depression.

article thumbnail

Best strains and terpenes for migraine relief

The Cannigma

The authors noted that while “promising data are emerging on the possible role of ECS in migraine…proper placebo-controlled trials are needed to establish a therapeutic role for cannabinoids.” 1 A 2008 study found serotonin and endocannabinoid levels, including anandamide, were lower in people with chronic migraines.

Terpenes 132
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

SciSparc Announces Positive Topline Results For Proprietary Pain Management Compound In Pre-Clinical Study

Cannabis Law Report

Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and Chronic Pain. Key findings from the pre-clinical trial are as follows: SCI-160 significantly alleviates pain up to 6 hours after injection as compared with vehicle-treated animals. TEL AVIV, Israel , Aug.

article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Only one article appeared in the MJA in 2000 and again in 2001. Conclusions. 2016 ; Sznitman et al. years (Atakan 2012 ).

article thumbnail

Meritas Law Firms Worldwide Article: Global Cannabis Industry: The Essential Primer

Cannabis Law Report

THC is just one of the cannabinoids in the Cannabis sativa L. The other major cannabinoid of particular interest commercially is cannabidiol (CBD). All told, the global legal cannabis industry, including dried cannabis and products containing cannabinoids, was estimated at US $11.9 The sky’s the limit.

Law 40